215 related articles for article (PubMed ID: 23850196)
1. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
[TBL] [Abstract][Full Text] [Related]
2. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
4. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
Miret JJ; Kirschmeier P; Koyama S; Zhu M; Li YY; Naito Y; Wu M; Malladi VS; Huang W; Walker W; Palakurthi S; Dranoff G; Hammerman PS; Pecot CV; Wong KK; Akbay EA
J Immunother Cancer; 2019 Feb; 7(1):32. PubMed ID: 30728077
[TBL] [Abstract][Full Text] [Related]
6. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
7. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.
Vollbrecht T; Stirner R; Tufman A; Roider J; Huber RM; Bogner JR; Lechner A; Bourquin C; Draenert R
AIDS; 2012 Jul; 26(12):F31-7. PubMed ID: 22526518
[TBL] [Abstract][Full Text] [Related]
8. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients.
Wang S; Fu Y; Ma K; Liu C; Jiao X; Du W; Zhang H; Wu X
Clin Transl Oncol; 2014 Jul; 16(7):616-22. PubMed ID: 24193866
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
[TBL] [Abstract][Full Text] [Related]
10. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.
Kalathil S; Lugade AA; Miller A; Iyer R; Thanavala Y
Cancer Res; 2013 Apr; 73(8):2435-44. PubMed ID: 23423978
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
12. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
Rodriguez PC; Ernstoff MS; Hernandez C; Atkins M; Zabaleta J; Sierra R; Ochoa AC
Cancer Res; 2009 Feb; 69(4):1553-60. PubMed ID: 19201693
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
[TBL] [Abstract][Full Text] [Related]
14. The proportion and function of peripheral myeloid-derived suppressor cells do not correlate with systemic inflammation in chronic obstructive pulmonary disease.
Tan DB; Fernandez S; Price P; Moodley YP
Hum Immunol; 2014 Jan; 75(1):5-9. PubMed ID: 24090682
[TBL] [Abstract][Full Text] [Related]
15. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases.
Janols H; Bergenfelz C; Allaoui R; Larsson AM; Rydén L; Björnsson S; Janciauskiene S; Wullt M; Bredberg A; Leandersson K
J Leukoc Biol; 2014 Nov; 96(5):685-93. PubMed ID: 24929004
[TBL] [Abstract][Full Text] [Related]
16. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
Srivastava MK; Bosch JJ; Thompson JA; Ksander BR; Edelman MJ; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Oct; 57(10):1493-504. PubMed ID: 18322683
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
Raychaudhuri B; Rayman P; Ireland J; Ko J; Rini B; Borden EC; Garcia J; Vogelbaum MA; Finke J
Neuro Oncol; 2011 Jun; 13(6):591-9. PubMed ID: 21636707
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.
Flörcken A; Takvorian A; Singh A; Gerhardt A; Ostendorf BN; Dörken B; Pezzutto A; Westermann J
Immunol Lett; 2015 Dec; 168(2):260-7. PubMed ID: 26462434
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
Sinha P; Okoro C; Foell D; Freeze HH; Ostrand-Rosenberg S; Srikrishna G
J Immunol; 2008 Oct; 181(7):4666-75. PubMed ID: 18802069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
